Biotech | July 10, 2022
WuXi XDC and AbTis sign MoU for manufacturing of antibody drug conjugates
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
Agreement to co-develop artificial intelligence (AI) technology for the application in peptide drug design
This investment will facilitate a Cipla entity's strategic participation in the Poe diagnostics and AMR space through the design, development, and manufacturing of microfluidics-based technologies
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
Becomes the first airline globally to develop and launch sustainable, temperature-controlled containers for the transportation of pharmaceuticals
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Bayer now present in four of the largest biotechnology hubs in the United States
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
This MoU will further strengthen relations between India and the USA within the framework of international scientific and technological cooperation in fields of mutual interest.
Leading this effort was Cytel’s principal research scientist and Professor of Health Research Methods at McMaster University in Canada, Dr. Edward Mills
Subscribe To Our Newsletter & Stay Updated
